Stock A1LN34 ALNYLAM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Alnylam Pharmaceuticals, Inc. Stock Sao Paulo

Equities

A1LN34

BRA1LNBDR003

Biotechnology & Medical Research

Market Closed - Sao Paulo
Other stock markets
 12:21:50 2024-06-28 pm EDT 		5-day change 1st Jan Change
67.55 BRL +78.70% Intraday chart for Alnylam Pharmaceuticals, Inc. +52.86% +51.29%
Jun. 28 UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
Jun. 27 Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT

Financials

Sales 2024 * 1.88B 10.49B Sales 2025 * 2.3B 12.87B Capitalization 30.74B 172B
Net income 2024 * -455M -2.55B Net income 2025 * -226M -1.26B EV / Sales 2024 * 15.8 x
Net cash position 2024 * 1.08B 6.05B Net cash position 2025 * 492M 2.75B EV / Sales 2025 * 13.1 x
P/E ratio 2024 *
-68.1 x
P/E ratio 2025 *
-148 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.58%
More Fundamentals * Assessed data

Chart Alnylam Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Alnylam Pharmaceuticals, Inc.

UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study MT
TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating MT
Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating MT
Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating MT
Out with AI, in with defensive stocks Our Logo
Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating MT
Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating MT
More news

Latest transcript on Alnylam Pharmaceuticals, Inc.

Logo Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. - Special Call
More transcripts

Analyst Recommendations on Alnylam Pharmaceuticals, Inc.

UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing MT
More recommendations

Press releases Alnylam Pharmaceuticals, Inc.

Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor AQ
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024 AQ
Alnylam Pharmaceuticals : HELIOS-B Topline Results Transcript PU
Alnylam Pharmaceuticals : HELIOS-B Topline Results PU
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations BU
More press releases

News in other languages on Alnylam Pharmaceuticals, Inc.

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...
Los resultados del fármaco de Alnylam Pharmaceutical se consideran el "mejor escenario posible" -- Market Talk
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...
ETF der Woche: Auf die Wende der Biotechs setzen
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech
More news

Quotes and Performance

1 day+78.70%
1 week+52.86%
Current month+76.37%
1 month+76.37%
3 months+86.45%
6 months+51.29%
Current year+51.29%
More quotes

Highs and lows

1 week
46.27
Extreme 46.27
69.63
1 month
41.29
Extreme 41.29
69.63
Current year
36.23
Extreme 36.23
69.63
1 year
36.23
Extreme 36.23
69.63
3 years
29.85
Extreme 29.85
69.63
5 years
29.85
Extreme 29.85
69.63
10 years
29.85
Extreme 29.85
69.63
More quotes

Managers and Directors - Alnylam Pharmaceuticals, Inc.

Managers TitleAgeSince
Yvonne Greenstreet CEO
 Chief Executive Officer 61 16-09-18
Jeffrey Poulton DFI
 Director of Finance/CFO 56 19-08-12
Piyush Sharma CMP
 Compliance Officer - 22-09-20
Members of the board TitleAgeSince
David Pyott BRD
 Director/Board Member 70 15-12-17
Charles Sigal BRD
 Director/Board Member 72 22-08-21
Margaret Hamburg BRD
 Director/Board Member 68 19-01-09
More insiders

Quotes

Date Price Change Volume
24-06-28 67.55 0.00% 10
24-06-27 67.55 -0.19% 590
24-06-26 67.68 +36.20% 4
24-06-25 49.69 +3.56% 1

Delayed Quote Sao Paulo, June 28, 2024 at 12:21 pm EDT

More quotes

Company Profile

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Sector
Biotechnology & Medical Research
Calendar
2024-07-30 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Alnylam Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
243 USD
Average target price
248.5 USD
Spread / Average Target
+2.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+19.41% 45.51B
LONZA GROUP AG Stock Lonza Group AG
+38.65% 39.36B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.52B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.61% 10.64B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. A1LN34 Stock